Skip to content
2000
Volume 19, Issue 15
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Transthyretin is a homotetrameric protein that carries thyroxine and retinol binding protein in plasma and is associated with a variety of amyloid diseases. One approach to the potential treatment of TTR amyloidosis is the stabilization of the native tetramer, over the dissociative transition state, through the binding of small molecules; this increases the kinetic barrier for tetramer dissociation and prevents protein misfolding. Several molecules discovered through focused screening, or created utilizing the structure-based design, were studied to identify the structural features that could make up for a good candidate drug. In this review, we examine several different chemical classes of TTR fibril formation inhibitors, highlighting the structural modifications that have led to an improvement or to a decrease of their potency and/or selectivity.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986712800269326
2012-05-01
2025-06-11
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986712800269326
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test